Economic Impact of Irritable Bowel Syndrome: What Does the Future Hold?

home / publications / supplement / 2005-04-vol11-n1suppl

Tegaserod Treatment for IBS: A Model of Indirect Costs

Dean G. Smith, PhD;Victoria Barghout, MSPH;Kristijan H. Kahler, SM

April 15th 2005

Economic Impact of Irritable Bowel Syndrome: What Does the Future Hold?

Brooks Cash, MD, FACP

April 15th 2005

ArticleINTRODUCTION

Effectiveness of Tegaserod Therapy on GI-related Resource Utilization in a Managed Care Population

Judith J. Stephenson, SM;Victoria Barghout, MSPH;Kristijan H. Kahler, SM;Joaquim Fernandes, BA;Jane F. Beaulieu, MSN;Samuel Joo, MS;Stephen J. Boccuzzi, PhD

April 15th 2005

Total Costs of IBS: Employer and Managed Care Perspective

Brooks Cash, MD, FACP;Sean Sullivan, JD;Victoria Barghout, MSPH

April 15th 2005

Budget Impact of Tegaserod on a Managed Care Organization Formulary

Michael A. Bloom, BA;Victoria Barghout, MSPH;Kristijan H. Kahler, SM;Judith Bentkover, PhD;Hannah Kurth, BA;Ian M. Gralnek, MD, MSHS;Brennan M. R. Spiegel, MD, MSHS

April 15th 2005

Participating Faculty

April 15th 2005

ArticleSUPPLEMENT CONTENT

Impairment in Work Productivity and Health-related Quality of Life in Patients With IBS

Bonnie B. Dean, PhD;Daniel Aguilar, MPH;Victoria Barghout, MSPH;Kristijan H. Kahler, SM;Feride Frech, MPH;David Groves, PhD;Joshua J. Ofman, MD

April 15th 2005

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions